SCHEMBL4606874

SCHEMBL4606874

COC(=O)c1ccc2c(C(=O)c3c(-c4ccccc4)noc3C)c[nH]c2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.51
KMT2A Q03164 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
POLB P06746 2/20 0.48
TSHR P16473 2/20 0.48
GAA P10253 2/20 0.48
KDM4E B2RXH2 2/20 0.48
HPGD P15428 2/20 0.48
CRHBP P24387 1/20 0.48
CRHR2 Q13324 1/20 0.48
HSD17B10 Q99714 1/20 0.48
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
MAPK1 P28482 2/20 0.46
MEN1 O00255 2/20 0.46
MAPT P10636 1/20 0.46
HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4603375 0.90 MAP2K4 (0.47) ALDH1A1KMT2ASMN1; SMN2POLBTSHR
SCHEMBL4604730 0.90 KMT2A (0.48) ALDH1A1KMT2ASMN1; SMN2POLBTSHR
SCHEMBL4605621 0.90 GABRA5 (0.50) ALDH1A1KMT2ASMN1; SMN2POLBTSHR
SCHEMBL4604079 0.85 GABRA5 (0.49) ALDH1A1KMT2ASMN1; SMN2KDM4ECYP1A2
SCHEMBL4607421 0.83 CYP1A2 (0.49) ALDH1A1KMT2ASMN1; SMN2POLBTSHR
SCHEMBL4604140 0.83 GABRA5 (0.49) ALDH1A1KMT2ASMN1; SMN2KDM4ECYP1A2
SCHEMBL4979623 0.83 GABRA5 (0.49) ALDH1A1KMT2ASMN1; SMN2KDM4ECYP1A2
SCHEMBL27718419 0.82 CYP1A2 (0.47) ALDH1A1KMT2ASMN1; SMN2POLBTSHR
SCHEMBL27739456 0.82 KMT2A (0.43) ALDH1A1KMT2ASMN1; SMN2TSHRGAA
SCHEMBL4604097 0.82 NPSR1 (0.53) ALDH1A1KMT2ASMN1; SMN2CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1937674-A1 ISOXAZOLE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-07-02 EP disclosed
US-7378435-B2 Aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives HOFFMANN-LA ROCHE INC. (US) 2008-05-27 US disclosed
WO-2007042420-A1 ISOXAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-04-19 WO disclosed
US-20070082936-A1 Aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives HOFFMANN-LA ROCHE INC. 2007-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070082936-A1 Aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives GABRA5, GABRA4, CHRNA5 ALDH1A1 297/4885KMT2A 2147/4885SMN1; SMN2 2837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.